NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

HDFC Life Insurance Company Ltd Shares Plummet on Weak Q4 Results

HDFC Life Insurance Company Ltd stock took a sharp hit in early trade on Friday, plummeting over 3 percent to Rs 610.40 and emerging as the top loser on the Nifty 50. The insurer's poor performance on key operating metrics in its fiscal fourth quarter results led to the decline.

Despite the broader market recording moderate gains, with the Nifty 50 up 0.33 percent at 24,276, HDFC Life shares have been underperforming, down 15.2 percent over the past one year, while the benchmark index has gained 1.8 percent during the same period.

Brokerages have highlighted multiple pressure points in HDFC Life's Q4 results, particularly around growth and profitability metrics. HSBC noted that the quarter was soft across parameters, including weakness in annualised premium equivalent (APE), margins, persistency, and embedded value (EV) growth. The brokerage maintained a 'buy' rating on HDFC Life shares with a target price of Rs 690 per share.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

BrokerageRatingTarget Price
HSBC'buy'Rs 690
JPMorgan'overweight'Rs 810

JPMorgan also pointed to subdued operating performance, noting that APE growth remained weak at 0.4 percent year-on-year, missing estimates. The value of new business (VNB) margin declined to 23.9 percent, leading to a drop in VNB, which also fell short of expectations. The brokerage added that competitive intensity weighed on retail growth, while pressure in the non-par (NPAR) segment is increasing. However, it retained an 'overweight' rating with a target price of Rs 810 per share.

HDFC Life reported a mixed performance for the January-March quarter, with key metrics coming in slightly below expectations. Total annualised premium equivalent (APE) stood at Rs 5,254 crore, marginally lower than the CNBC-TV18 poll estimate of Rs 5,329 crore. The value of new business (VNB) came in at Rs 1,261 crore versus estimates of Rs 1,269 crore. APE grew 1.3 percent year-on-year, but VNB declined 8.4 percent, with VNB margins compressing to 24 percent from 26.5 percent in the year-ago period.

For FY26, the insurer reported a 6 percent year-on-year rise in profit after tax at Rs 1,910 crore, while underlying profit growth stood at 16 percent after adjusting for one-off impacts. New business APE grew 8 percent during the year, with a two-year CAGR of 12 percent, while VNB stood at Rs 4,034 crore with margins at 24.2 percent. The company also recommended a final dividend of Rs 2.10 per share for FY26, with June 19, 2026 set as the record date.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Investor Takeaway

Investors should be cautious about HDFC Life's stock performance due to weak Q4 earnings and growth concerns.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.